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Room 11-76, New York, NY 10029, USASummary requires oxygen activation, which results in the generation ofAlcoholic (ALD) and non-alcoholic fatty liver diseases (NAFLD) are
clinical conditions leading to hepatocellular injury and inﬂamma-
tion resulting from alcohol consumption, high fat diet, obesity and
diabetes, among others. Oxidant stress is a major contributing fac-
tor to the pathogenesis of ALD and NAFLD. Multiple studies have
shown that generation of reactive oxygen species (ROS) is key for
the progression of fatty liver to steatohepatitis. Cytochrome P450
2E1 (CYP2E1) plays a critical role in ROS generation and CYP2E1
is also induced by alcohol itself. This review summarizes the role
of CYP2E1 in ALD and NAFLD.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Cytochrome P450 and oxidant stressThe cytochrome P450 super family is a group of hemecontaining
proteins with multiple functions including the metabolism of
xenobiotics such as drugs, toxins, carcinogens, and endogenous
substrates, such as fatty acids and steroids. The cytochrome
P450 enzymes catalyze a number of chemical reactions such as
peroxidation, dealkylation, mono-oxygenation, reduction, epoxi-
dation, and dehalogenation (reviewed in [3,14]). A major function
of the cytochrome P450 system is to convert non-polar to polar
compounds for conjugation by phase II enzymes or for direct
excretion.
Toxic metabolites are generated by cytochrome P450-
mediated metabolism, which in turn causes signiﬁcant cellular
injury. The catalytic activity of the cytochrome P450 enzymesJournal of Hepatology 20
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ROS are produced by the mitochondrial respiratory chain, the
cytochrome P450 system, auto-oxidation of heme proteins, the
NADPH oxidase complex, xanthine oxidase, oxidative enzymes,
and other cellular systems (reviewed in [3,19]). ROS are toxic to
cells since they react with macromolecules, denature proteins,
inactivate enzymes, and cause RNA and DNA damage. NADPH
oxidase-containing macrophages and neutrophils produce ROS
to remove foreign micro-organisms. ROS are also important in
signal transduction, cellular physiology and are involved in criti-
cal metabolic pathways. However, a high concentration of ROS is
deﬁnitively harmful.
A number of enzymatic and non-enzymatic mechanisms in
the body maintain physiological levels of ROS and prevent cellu-
lar damage by ROS. These mechanisms include superoxide dis-
mutase, catalase, glutathione peroxidase, glutathione
transferase, heme oxygenase, ceruloplasmin, ferritin, glutathione
(GSH), vitamin E, vitamin A, vitamin C, uric acid, and bilirubin
(reviewed in [3,19]). Under normal physiological conditions,
there is a balance between the rate of ROS generation and the
rate of ROS removal along with repair from ROS-induced cellular
damage. Oxidant stress is caused by excess ROS production,
which leads to apoptosis and necrosis. ROS also lead to a free rad-
ical chain reaction with unsaturated fatty acids generating toxic
lipid intermediates, a reaction magniﬁed by the presence of free
iron. Lipid peroxidation modiﬁes the integrity of cellular mem-
branes and damages proteins and DNA. There are three major
sites within hepatocytes for ROS generation, i.e., mitochondria,
peroxisomes, and the smooth endoplasmic reticulum.Oxidant stress in ALD and NAFLD
Oxidant stress is a pathogenic factor for the onset of ALD and
NAFLD. In vivo models of alcohol infusion induce lipid peroxida-
tion because of increased free radical formation and decreased
hepatic antioxidants such as GSH [15,22]. GSH is synthesized in
the cytosol and is translocated to the mitochondria. The liver is
the major organ excreting GSH into the plasma and the bile.
GSH levels decrease in both ALD and NAFLD animal models
suggesting either reduced endogenous antioxidant availability
or consumption of GSH to cope with the large amount of
pro-oxidants generated or perhaps both.13 vol. 58 j 395–398
Clinical Application of Basic ScienceKey Points
• Oxidant stress is key in the pathogenesis of ALD and
NAFLD
• Alcohol metabolism via cytochrome P450 2E1 
generates reactive oxygen species
• Polyunsaturated fatty acids further enhance alcohol-
induced liver injury
• Positive feedback loop between cytochrome P450
2E1 activation and insulin resistance contributes to the
progression of steatosis into steatohepatitis
In addition to GSH, other hepatic antioxidants such as vitamin
A, vitamin C, bilirubin, and enzymes such as superoxide dismu-
tase and catalase remove ROS. In vitro studies showed more oxi-
dant stress and cellular injury in hepatocytes isolated from
chronic alcohol-fed rats and in ethanol-treated HepG2 cells over-
expressing CYP2E1 when compared with the corresponding con-
trols [30]. Moreover, treatment with an inhibitor of alcohol
oxidation such as 4-methylpyrazole or an antioxidant such as
trolox, effectively prevented or reduced alcohol-induced toxicity,
pointing one more time at the importance of oxidant stress in the
pathogenesis of ALD [30].
CYP2E1, oxidant stress in ALD
ALD results from increased steatosis, inﬂammation, oxidant, and
nitrosative stress and mitochondrial dysfunction. Alcohol dehy-
drogenase (ADH) is the major enzyme oxidizing alcohol. The
involvement of cytochrome P450 in alcohol metabolism was ﬁrst
identiﬁed by Charles S. Lieber in his studies on the microsomal
ethanol-oxidizing system (MEOS) [18]. MEOS has a higher Km
than ADH in oxidizing alcohol and oxidizes alcohol to generate
acetaldehyde. The activity of MEOS increases in chronic alcohol
consumption partly due to the induction of cytochrome P450
enzymes.
Among the cytochrome P450 family, CYP2E1 has been identi-
ﬁed as the most relevant for ALD as it is highly inducible and it
has high catalytic activity for alcohol [18]. CYP2E1 is mainly
expressed in the liver, with hepatocytes showing the highest
expression, but it is also located in other organs such as the brain
and intestine. CYP2E1 is mainly located within the endoplasmic
reticulum (ER) although it is also expressed in the mitochondria
[23]. CYP2E1 metabolizes a variety of substances including multi-
ple drugs, polyunsaturated fatty acids, ethanol, acetaminophen
and most organic solvents. Multiple factors such as insulin, ace-
tone, leptin, adiponectin and cytokines regulate CYP2E1 mRNA
and protein expression [19].
Many CYP2E1 substrates induce their own metabolism as it
occurs with ethanol, which is particularly relevant to the devel-
opment of ALD. Previous studies have shown that alcohol toxicity
is reduced when CYP2E1 is inhibited using chemicals or in
Cyp2e1/ mice [5]. CYP2E1 expression and activity are higher
after chronic ethanol feeding compared with pair-fed mice con-
suming a control diet on a pair-feeding regimen [19].
During the catalytic cycle of CYP2E1, signiﬁcant amounts of
ROS are generated, which subsequently cause cellular damage.396 Journal of Hepatology 201Previous studies showed that increased cellular injury, lipid per-
oxidation, oxidant and nitrosative stress, and mitochondrial dam-
age occurred in livers from chronic ethanol-fed mice compared
with pair-fed mice. One of the reasons for the increase in CYP2E1
protein during chronic ethanol intake is decreased proteasomal
degradation, which increases CYP2E1 protein stability [12,27].
Recent work has shown that CYP2E1 activity correlates with
ethanol-induced liver injury and lipid peroxidation [7]. Inhibition
of CYP2E1 effectively blocked the ethanol-mediated lipid peroxi-
dation and reduced liver injury. In contrast, transgenic mice over-
expressing CYP2E1 [8], mice infected with an adenovirus to
overexpress Cyp2e1 and HepG2 cells transduced with an adenovi-
rus encoding the human CYP2E1 gene, all exacerbated oxidant
stress [4]. Endogenous GSH levels are a major factor in alcohol-
induced oxidant stress and CYP2E1 overexpression in HepG2 cells
induces GSH synthesis by transcriptional activation of gamma-
glutamylcysteine synthetase, the rate-limiting enzyme in GSH
synthesis [20].CYP2E1 and NAFLD
In addition to ethanol, CYP2E1 also metabolizes polyunsaturated
fatty acids such as linoleic acid and arachidonic acid to generate
x-hydroxylated fatty acids [3]. The x-hydroxylated fatty acids
are further metabolized to dicarboxylic fatty acids that are cyto-
toxic at high concentrations. Indeed, increased CYP2E1 protein
expression and activity were found in obesity, fatty liver and
non-alcoholic steatohepatitis (NASH) in both humans and
rodents (reviewed in [3]). Feeding rats with a high fat diet also
increased CYP2E1, although some studies showed that fasting
or prolonged starvation also elevated CYP2E1. The role of CYP2E1
in the pathogenesis of NAFLD is under active investigation.
Multiple studies have shown the signiﬁcance of increased
CYP2E1 expression and electron leakage from the mitochondrial
respiratory chain in inducing oxidant stress in NAFLD [6,28].
CYP2E1 expression and activation are induced in fatty liver dis-
ease and ROS are generated by activated CYP2E1 resulting in oxi-
dant stress. This contributes to the progression from steatosis to
steatohepatitis. Chtioui et al. showed a signiﬁcantly higher degree
of steatosis in patients with NASH than in patients with NAFLD
[9]. No signiﬁcant difference in CYP2E1 expression was observed
between simple fatty liver and NASH; however, CYP2E1 activity
correlated with the extent of steatosis [9]. CYP2E1 is induced in
rats fed a high fat diet compared to rats fed a low fat diet suggest-
ing that the amount of fat consumed is critical for CYP2E1 induc-
tion [26]. These studies suggest that the amount of fat in the liver
is important for the pathogenesis of NASH by increasing CYP2E1
and by rendering the liver more susceptible to noxious sub-
stances such as ROS. Since CYP2E1 is involved in the metabolism
of fatty acids, inhibiting CYP2E1 may reduce oxidant stress but
potentiate steatosis.
Correlation between CYP2E1 expression and lipid peroxida-
tion was observed in obese patients [25]. Although there was
increased serum GSH, signiﬁcant hepatic GSH reduction occurred
in patients with steatosis and steatohepatitis. This reduction in
GSH may be the result of fatty acid toxicity. An in vitro study
showed a dose-dependent increase in GSH content in HepG2 cells
in response to increasing doses of oleic acid or palmitic acid.
However, oleic acid but not palmitic acid sustained GSH levels
due to the fact that palmitic acid reduced cell viability, indicating
speciﬁcity of fatty acids in inducing liver toxicity and cell death3 vol. 58 j 395–398
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Fig. 1. A signiﬁcant amount of CYP2E1 is produced and activated by alcohol
and fatty acids in ALD and NAFLD, respectively. Alcohol is metabolized by ADH
and CYP2E1 generating toxic intermediates such as acetaldehyde, acetate and free
radicals. In addition, CYP2E1 metabolizes fatty acids generating x-hydroxylated
fatty acids. CYP2E1 activity induces ROS overproduction and results in oxidant
stress and cellular damage. GSH, an endogenous antioxidant, is reduced in both
ALD and NAFLD. This reduction promotes oxidant stress.
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[10]. Further studies are warranted to dissect how changes in
speciﬁc fatty acids condition the development and progression
of ALD, NAFLD and NASH.
It is worth mentioning that compensatory mechanisms could
occur within the cytochrome P450 enzymes. Other cytochrome
P450s, such as CYP4A10 and CYP4A14 are induced in Cyp2e1/
mice with an increase in ROS and oxidant stress in a NASH mur-
ine model [17]. This suggests that CYP2E1 may not be the only
cytochrome P450 enzyme promoting oxidant stress. This com-
pensatory pathway was further clariﬁed by treating wild type
mice with CYP2E1 and CYP4A antibodies. Only the CYP2E1 anti-
body showed inhibition of lipid peroxidation, a hallmark of
ALD. In contrast, the CYP4A antibody but not the CYP2E1 anti-
body protected from lipid peroxidation when treating Cyp2e1/
mice with a methionine and choline-deﬁcient diet compared to
a methionine and choline-sufﬁcient diet [17]. This indicates that
CYP4A induction could be an alternative pathway when CYP2E1
is less available [28].
It is suggested that the induction of CYP2E1 in NAFLD is an
adaptive response to prevent lipid overload as CYP2E1-mediated
x-hydroxylation of fatty acids is an alternative pathway to perox-
isomal and mitochondrial b-oxidation. However, further studies
are needed to clarify this theory.
Insulin resistance, CYP2E1 in ALD AND NAFLD
Insulin resistance and hyperinsulinemia play a key role in hepatic
fat accumulation and are common to both ALD and NAFLD.
Cyp2e1/ mice showed protection from a high-fat diet-induced
insulin resistance [1,31]. In contrast, mice knocked in for the
human CYP2E1 transgene showed increased insulin resistance,
oxidant stress, more hepatic steatosis and liver injury [16].
Indeed, insulin is known to decrease CYP2E1 expression [29].
Thus, insulin resistance may increase CYP2E1 expression and
activity via the high concentration of ketone bodies produced
from persistent mitochondrial fatty acid oxidation. Ketone bodies
stabilize CYP2E1 and prevent its degradation. The increase in
CYP2E1 and enhanced insulin resistance seem to promote each
other by creating a positive feedback loop that may eventually
make steatosis progress to steatohepatitis as oxidant stress
increases. The mechanism by how CYP2E1 and insulin resistance
interact requires further investigation. Both CYP2E1 activation
and insulin resistance are common to ALD and NAFLD; thus,
inhibiting CYP2E1 may disrupt this feedback loop and reduce
insulin resistance and liver injury.Clinical implications and perspectives
The toxicity induced by CYP2E1 in ALD and NAFLD should be fur-
ther investigated. Indeed, it is necessary to identify the role of
microsomal compared to mitochondrial CYP2E1 as they could
contribute differently to these pathologies. The regulation of
CYP2E1 expression and activity is of clinical importance since
CYP2E1 plays a central role in ALD and NAFLD. CYP2E1 is trig-
gered by both exogenous substrates such as ethanol, and endog-
enous substrates such as polyunsaturated fatty acids, and it
induces injury by generating ROS and lipid peroxidation reac-
tions. The reduction of endogenous antioxidants in ALD and
NAFLD may further enhance CYP2E1-induced lipid peroxidation,
oxidant stress and cellular toxicity. Replenishing the amount ofJournal of Hepatology 201antioxidants could target CYP2E1-induced oxidant stress by
cleaning free radicals. Fig. 1 depicts the activation of CYP2E1 by
alcohol and fatty acids in generating ROS, which induces oxidant
stress and cellular damage. Furthermore, reduced endogenous
antioxidants enhance oxidant stress.
The use of CYP2E1 inhibitors, such as chlormethiazole and
polyenylphosphatidylcholine, showed partial but effective pro-
tection in ethanol-induced liver injury [2,13]. This partial protec-
tion suggested that CYP2E1 may not be the only source of
pro-oxidants. Interestingly, CYP2E1-expressing cells showed an
increase not only in GSH, but also in antioxidant enzymes such
as glutathione-S-transferase, catalase and heme-oxygenase
[19,21]. Treatment with antioxidants prevented the induction of
these enzymes suggesting that CYP2E1-derived ROS may be
responsible for the transcription and activation of the antioxidant
genes [24]. The induction of CYP2E1 could also be protective in
eliminating noxious substances and regulating various metabolic
pathways in response to stress. However, some CYP2E1 inhibi-
tors, for example YH439, a novel hepatoprotective agent, may
inhibit other cytochrome P450 enzymes and affect other meta-
bolic pathways, hence, causing cellular toxicity.Concluding remarks
Evidence from experimental and clinical data shows that CYP2E1
is a multifunctional protein metabolizing various endogenous
and exogenous substrates and generating ROS. CYP2E1 also
induces other factors, for example Nrf2, to protect against
CYP2E1-induced oxidant stress [11]. This suggests that CYP2E1
has adaptive responses to condition the oxidant stress induced
during its metabolic activity. However, further studies are war-
ranted to understand how CYP2E1 expression and activity regu-
late hepatotoxic and hepatoprotective pathways. Moreover,
how endogenous antioxidants are depleted in ALD and NAFLD
is not clear. Studies on various CYP2E1 inhibitors, antioxidant
replenishment and alternative cytochrome P450 enzymes could
provide relevant clinical information for the development of
ALD and NAFLD treatments.3 vol. 58 j 395–398 397
Clinical Application of Basic Science
Financial support
US Public Health Service Grants 5R01 DK069286 and 2R56
DK069286 from the National Institute of Diabetes and Digestive
and Kidney Diseases (N.N.). US Public Health Service Grants
5P20 AA017067, 5P20 AA017067-01S1 and 5P20 AA017067-
03S1 from the National Institute on Alcohol Abuse and Alcohol-
ism (N.N.).Conﬂict of interest
The Authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.Acknowledgments
We thank Dr. Arthur I. Cederbaum (Mount Sinai School of Medi-
cine) for his advice in the preparation of this review.
References
[1] Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical
role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-
induced non-alcoholic steatohepatitis. J Hepatol 2012;57:860–866.
[2] Aleynik MK, Leo MA, Aleynik SI, Lieber CS. Polyenylphosphatidylcholine
opposes the increase of cytochrome P-4502E1 by ethanol and corrects its
iron-induced decrease. Alcohol Clin Exp Res 1999;23:96–100.
[3] Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased
expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease:
mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol
2011;35:630–637.
[4] Bai J, Cederbaum AI. Adenovirus-mediated expression of CYP2E1 produces
liver toxicity in mice. Toxicol Sci 2006;91:365–371.
[5] Bardag-Gorce F, Yuan QX, Li J, French BA, Fang C, Ingelman-Sundberg M,
et al. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of
proteasome activity by alcohol. Biochem Biophys Res Commun
2000;279:23–29.
[6] Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in
NASH: causes, consequences and possible means to prevent it. Mitochon-
drion 2006;6:1–28.
[7] Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, et al.
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation
levels and affects hepatic cytochrome P-450 protein content. Ann Surg
2010;251:1041–1048.
[8] Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, et al. The
impact of CYP2E1 on the development of alcoholic liver disease as studied in
a transgenic mouse model. J Hepatol 2009;50:572–583.
[9] Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression
and activity of the cytochrome P450 2E1 in patients with nonalcoholic
steatosis and steatohepatitis. Liver Int 2007;27:764–771.
[10] Garcia MC, Amankwa-Sakyi M, Flynn TJ. Cellular glutathione in fatty liver
in vitro models. Toxicol In Vitro 2011;25:1501–1506.
[11] Gong P, Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and
HepG2 cells and protects against oxidative stress caused by CYP2E1.
Hepatology 2006;43:144–153.398 Journal of Hepatology 201[12] Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture: Cyp2e1. Drug Metab
Dispos 2007;35:1–8.
[13] Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, et al. Inhibition of
ethanol-induced liver disease in the intragastric feeding rat model by
chlormethiazole. Proc Soc Exp Biol Med 2000;224:302–308.
[14] Guengerich FP. Mammalian Cytochrome P450. Boca Raton: CRC Press; 1987.
[15] Iimuro Y, Bradford BU, Yamashina S, Rusyn I, Nakagami M, Enomoto N, et al.
The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects
against liver injury due to chronic enteral ethanol exposure in the rat.
Hepatology 2000;31:391–398.
[16] Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-
speciﬁc cytochrome P4502E1 impairs hepatic insulin signaling in a trans-
genic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol
Hepatol 2009;21:973–983.
[17] Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1
and CYP4A as microsomal catalysts of lipid peroxides in murine nonalco-
holic steatohepatitis. J Clin Invest 2000;105:1067–1075.
[18] Lieber CS. Cytochrome P-4502E1: its physiological and pathological role.
Physiol Rev 1997;77:517–544.
[19] Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic
Biol Med 2008;44:723–738.
[20] Mari M, Cederbaum AI. CYP2E1 overexpression in HepG2 cells induces
glutathione synthesis by transcriptional activation of gamma-glutamylcys-
teine synthetase. J Biol Chem 2000;275:15563–15571.
[21] Mari M, Cederbaum AI. Induction of catalase, alpha, and microsomal
glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and
protection against short-term oxidative stress. Hepatology
2001;33:652–661.
[22] Nanji AA, Zhao S, Sadrzadeh SM, Dannenberg AJ, Tahan SR, Waxman DJ.
Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation
is associated with severe liver injury in ﬁsh oil–ethanol-fed rats. Alcohol Clin
Exp Res 1994;18:1280–1285.
[23] Neve EP, Ingelman-Sundberg M. Molecular basis for the transport of
cytochrome P450 2E1 to the plasma membrane. J Biol Chem
2000;275:17130–17135.
[24] Nieto N, Mari M, Cederbaum AI. Cytochrome P450 2E1 responsiveness in the
promoter of glutamate-cysteine ligase catalytic subunit. Hepatology
2003;37:96–106.
[25] Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al.
Relationship between in vivo chlorzoxazone hydroxylation, hepatic cyto-
chrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver
disease patients. Hepatol Res 2006;34:57–63.
[26] Osabe M, Sugatani J, Fukuyama T, Ikushiro S, Ikari A, Miwa M. Expression of
hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased
expression of the nuclear constitutive androstane receptor and peroxisome
proliferator-activated receptor alpha in male rats fed a high-fat and high-
sucrose diet. Drug Metab Dispos 2008;36:294–302.
[27] Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by
protein stabilization. Role of ubiquitin conjugation in the rapid degradation
of CYP2E1. J Biol Chem 1995;270:29632–29635.
[28] Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepa-
titis: II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol
Gastrointest Liver Physiol 2001;281:G1135–G1139.
[29] Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional
and posttranscriptional regulation of CYP2E1 expression. Hepatology
2002;35:263–273.
[30] Wu D, Cederbaum AI. Ethanol-induced apoptosis to stable HepG2 cell lines
expressing human cytochrome P-4502E1. Alcohol Clin Exp Res
1999;23:67–76.
[31] Zong H, Armoni M, Harel C, Karnieli E, Pessin JE. Cytochrome P-450 CYP2E1
knockout mice are protected against high-fat diet-induced obesity and
insulin resistance. Am J Physiol Endocrinol Metab 2012;302:E532–E539.3 vol. 58 j 395–398
